Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
EGF
NSCLC
antibodies affinity
cancer vaccine
surrogate biomarker
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
25 05 2020
25 05 2020
Historique:
entrez:
14
9
2020
pubmed:
15
9
2020
medline:
15
9
2020
Statut:
epublish
Résumé
We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advanced non-small-cell lung cancer (NSCLC) patients. A phase III trial was designed using an optimized immunization schedule. It included higher antigen dose and injections at multiple sites. Immune response and circulating biomarkers were studied in a subset of patients. EGF-specific antibody titers, IgG subclasses, peptide immunodominance and circulating biomarkers were assessed by ELISA. EGF: epidermal growth factor; EGFR: epidermal growth factor receptor; Ab: antibody; AR: amphiregulin; NSCLC: non-small-cell lung cancer; rhEGF: recombinant human epidermal growth factor; BSC: best supportive care; TGFα: tumor growth factor alpha; IL-8: interleukin 8; MAb: monoclonal antibody; SPR: surface plasmon resonance.
Identifiants
pubmed: 32923124
doi: 10.1080/2162402X.2020.1762465
pii: 1762465
pmc: PMC7458606
doi:
Substances chimiques
Biomarkers
0
Epidermal Growth Factor
62229-50-9
Types de publication
Journal Article
Langues
eng
Pagination
1762465Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Front Immunol. 2013 Aug 09;4:235
pubmed: 23950757
Cancer Res. 2005 Oct 15;65(20):9176-84
pubmed: 16230376
Expert Rev Vaccines. 2016;15(3):295-311
pubmed: 26641943
Endocr Relat Cancer. 2001 Mar;8(1):11-31
pubmed: 11350724
Annu Rev Biochem. 1979;48:193-216
pubmed: 382984
Oncology. 1992;49(2):157-61
pubmed: 1574253
Lancet. 2012 Nov 24;380(9856):1797-9
pubmed: 23079587
Cancer Immunol Immunother. 2015 Dec;64(12):1609-21
pubmed: 26498005
Cancer Sci. 2017 Jan;108(1):53-60
pubmed: 27783866
BMC Cancer. 2016 Jun 06;16:354
pubmed: 27268079
Ann Oncol. 2003 Mar;14(3):461-6
pubmed: 12598354
J Allergy Clin Immunol. 2012 Jan;129(1):128-35
pubmed: 21996342
Curr Opin Immunol. 2015 Jun;34:9-15
pubmed: 25576665
Int J Cancer. 2016 Sep 15;139(6):1391-401
pubmed: 27170523
Methods Mol Med. 2004;94:299-320
pubmed: 14959837
Prog Growth Factor Res. 1992;4(1):1-24
pubmed: 1355372
Oncol Lett. 2016 Dec;12(6):4493-4504
pubmed: 28105158
Sci Rep. 2017 Aug 16;7(1):8322
pubmed: 28814733
Cancer Res. 2002 Mar 1;62(5):1364-9
pubmed: 11888906
Curr Pharm Des. 2016;22(39):5887-5898
pubmed: 27426127
Transplantation. 2018 Jan;102(1S Suppl 1):S7-S13
pubmed: 29266057
Hum Vaccin. 2007 Jan-Feb;3(1):8-13
pubmed: 17204867
Vaccine. 2017 Jun 16;35(28):3582-3590
pubmed: 28536029
PDA J Pharm Sci Technol. 2015 May-Jun;69(3):399-416
pubmed: 26048746
Clin Cancer Res. 1998 Jan;4(1):241-9
pubmed: 9516978
Clin Cancer Res. 2008 Feb 1;14(3):840-6
pubmed: 18245547
J Immunother. 2009 Jan;32(1):92-9
pubmed: 19307998
Clin Cancer Res. 2009 Apr 1;15(7):2397-405
pubmed: 19276250
Vaccine. 2008 Aug 26;26(36):4647-54
pubmed: 18640164
J Cancer Res Clin Oncol. 2013 Mar;139(3):367-78
pubmed: 23099994
Front Immunol. 2017 Mar 13;8:269
pubmed: 28348561
Am J Clin Oncol. 2015 Aug;38(4):422-30
pubmed: 24685885
J Mol Recognit. 2007 Jan-Feb;20(1):22-31
pubmed: 17036306
Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
pubmed: 7612182
J Immunother Emphasis Tumor Immunol. 1996 May;19(3):176-83
pubmed: 8811492
Clin Exp Allergy. 2009 Apr;39(4):469-77
pubmed: 19222496
Oncogene. 2008 Jun 26;27(28):3944-56
pubmed: 18297114
Clin Cancer Res. 2000 Dec;6(12):4607-9
pubmed: 11156209
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Retrovirology. 2014 May 29;11:41
pubmed: 24884783
Sci Rep. 2016 Aug 17;6:31666
pubmed: 27530713
Ann Oncol. 2006 May;17 Suppl 5:v72-8
pubmed: 16807469
Cancer Biol Ther. 2006 Feb;5(2):145-9
pubmed: 16357522
J Interferon Cytokine Res. 2001 Mar;21(3):167-71
pubmed: 11331039
Clin Cancer Res. 2016 Aug 1;22(15):3782-90
pubmed: 26927662
Target Oncol. 2014 Sep;9(3):205-14
pubmed: 23821377
BMC Cancer. 2013 Feb 02;13:49
pubmed: 23374602
J Immunol. 2011 Oct 15;187(8):4229-35
pubmed: 21930965
J Immune Based Ther Vaccines. 2011 Oct 24;9:7
pubmed: 22024351